Expression of TGFβ type-II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions

Cancer

Volumn 110, Issue 7, 2007, Pages 1527-1531

  Muñoz Antonia, Teresita ^a   Muro Cacho, Carlos ^b   Sharma, Swati ^a   Cantor, Alan ^a   Bepler, Gerold ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Ki 67; MCM2; Premalignant; Transforming growth factor

Indexed keywords

DNA FRAGMENT; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR MARKER; CELL CYCLE PROTEIN; MCM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; LUNG INJURY; PILOT STUDY; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION; CHEMISTRY; LUNG; LUNG TUMOR; METABOLISM; METAPLASIA; PATHOLOGY;

APOPTOSIS; CARCINOMA IN SITU; CELL CYCLE PROTEINS; CELL PROLIFERATION; DNA FRAGMENTATION; HUMANS; KI-67 ANTIGEN; LUNG; LUNG NEOPLASMS; METAPLASIA; NUCLEAR PROTEINS; PILOT PROJECTS; PRECANCEROUS CONDITIONS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 34648836711     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22937     Document Type: Article

References (17)

1. rd Edition. Berlin, Germany: Springer; 1999.
2. Wistuba II, Behrens C, Virmani AK, et al. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999;59:1973-1979.
3. Tan DF, Huberman JA, Hyland A, et al. MCM2-a promising marker for premalignant lesions of the lung: a cohort study. BMC Cancer. 2001;1:6.
4. Muro-Cacho CA, Anderson M, Cordero J, Munoz-Antonia T. Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma. Clin Cancer Res. 1999;5:1243-1248.
5. Anderson M, Muro-Cacho C, Cordero J, Livingston S, Munoz-Antonia T. Transforming growth factor beta receptors in verrucous and squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1999;125:849-854.
6. Todorov IT, Werness BA, Wang HQ, et al. HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. Lab Invest. 1998;78:73-78.
7. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2:210-219.
8. Masui T, Wakefield LM, Lechner JF, LaVeck MA, Sporn MB, Harris CC. Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal bronchial epithelial cells. Proc Natl Acad Sci U S A. 1986;83:2438-2442.
9. Norgaard P, Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaarrd Poulsen H. Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer lines is associated with expression of the type II receptor. Br J Cancer. 1994;69:802-808.
10. Damstrup L, Rygaard K, Spang-Thomsen M, Skovgaard Poulsen H. Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. Br J Cancer. 1993;67:1015-1021.
11. Geiser AG, Burmester JK, Webbink R, Roberts AB, Sporn MB. Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J Biol Chem. 1992;267:2588-2593.
12. Serrero G, Zhou J, Mills D, LePak N. Decreased transforming growth factor-beta response and binding in insulin-independent teratoma-derived cell lines with increased tumorigenic properties. J Cell Physiol. 1991;149:503-511.
13. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts A, Sporn MB. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci U S A. 1994;91:8772-8776.
14. Gobbi H, Dupont WD, Arteaga CL, Simpson JF, Olson SJ, Schuyler PA, Page DL. Loss of transforming growth factor beta receptor II expression in epithelial hyperplasia without atypia increases the subsequent breast cancer risk. Mod Pathol. 1999;12:21A.
15. Gobbi H, Arteaga CL, Jensen RA, et al. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology. 2000;36:168-177. Comment in: Histopathology. 2000;36:178-180.
16. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
17. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.